Cambridge, MA-based Ironwood Pharmaceuticals (NASDAQ: [[ticker:IRWD]]) said today that the underwriters of its IPO on February 2 have exercised all their options to buy 2.5 million additional shares. That means the company has raised an extra $28 million, and after deducting all expenses from this and the first part of the transaction, the company has netted $203 million from the IPO. JP Morgan Securities, Morgan Stanley, Credit Suisse Securities, BofA Merrill Lynch, and Wedbush PacGrow Life Sciences were the underwriters. Ironwood shares have climbed slightly since the initial price was set, closing at $11.50 yesterday.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
